|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
| 化学式 | C87H170N52O19S2.C2HF3O2 |
|||
| 分子量 | 2426.77 | CAS No. | 1222186-26-6 | |
| Solubility (25°C)* | 体外 | Water | 100 mg/mL (41.2 mM) | |
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
||||
| 製品説明 | GO-203 is a D-amino acid cell-penetrating peptide inhibitor of MUC1-C dimerization and thereby its oncogenic function. |
|---|---|
| in vitro | GO-203 inhibits MUC1-C homodimerization which blocks its oncogenic function. Treatment of MUC1-overexpressing SKCO-1 and Colo-205 colon cancer cells with this compound is associated with downregulation of the TP53-inducible glycolysis and apoptosis regulator (TIGAR) protein. This chemical regulates AKT-S6K1-elF4A signaling in colorectal cancer cells. Targeting MUC1-C with it inhibits p-AKT in colorectal cancer cells. This treatment also results in increases in reactive oxygen species (ROS) and loss of mitochondrial transmembrane potential[1]. |
| in vivo | GO-203 is effective in inhibiting growth and survival of MUC1-positive colorectal cancer cells in mouse xenograft models. It is also effective in xenografts models of breast, prostate, lung and certain hematologic malignancy[1]. |
| 細胞アッセイ | 細胞株 | Human SW480 and LOVO colorectal cancer cells |
|---|---|---|
| 濃度 | 5 μM | |
| 反応時間 | 48 h | |
| 実験の流れ | To assess cell viability, 20,000–30,000 cells are plated and cultured for 48 h. GO-203 and CP-2 are added at 5 μM every day for six days. Cell viability is measured by trypan blue exclusion. | |
| 動物実験 | 動物モデル | BALB/c nu/nu male/female mice with xenograft tumor |
| 投薬量 | 18 mg/kg | |
| 投与方法 | i.p. |
|
| MUC1-C dependence in treatment-resistant prostate cancer uncovers a target for antibody-drug conjugate therapy [ JCI Insight, 2025, 10(14)e190924] | PubMed: 40553569 |
| Activation of APOBEC3 cytidine deaminases and endogenous retroviruses is integrated by MUC1-C in NSCLC cells [ Cell Death Discov, 2025, 11(1):372] | PubMed: 40781226 |
| MUC1-C dependency in drug resistant HR+/HER2- breast cancer identifies a new target for antibody-drug conjugate treatment [ NPJ Breast Cancer, 2025, 11(1):39] | PubMed: 40287441 |
| Hypoxia induces ROS-resistant memory upon reoxygenation in vivo promoting metastasis in part via MUC1-C [ Nat Commun, 2024, 15(1):8416] | PubMed: 39341835 |
| Dexamethasone Selectively Inhibits Detachment of Metastatic Thyroid Cancer Cells during Random Positioning [ Cancers (Basel), 2023, 15(6)1641] | PubMed: 36980530 |
| Dexamethasone Selectively Inhibits Detachment of Metastatic Thyroid Cancer Cells during Random Positioning [ Cancers (Basel), 2023, 15(6)1641] | PubMed: 36980530 |
| Gasdermin E mediates resistance of pancreatic adenocarcinoma to enzymatic digestion through a YBX1-mucin pathway [ Nat Cell Biol, 2022, 24(3):364-372] | PubMed: 35292781 |
| Mucin 1 Inhibits Ferroptosis and Sensitizes Vitamin E to Alleviate Sepsis-Induced Acute Lung Injury through GSK3β/Keap1-Nrf2-GPX4 Pathway [ Oxid Med Cell Longev, 2022, 2022:2405943] | PubMed: 35910848 |
| Protective and predictive role of Mucin1 in sepsis-induced ALI/ARDS. [ Int Immunopharmacol, 2020, 1;83:106438] | PubMed: 32247267 |
| Paclitaxel alleviated sepsis-induced acute lung injury by activating MUC1 and suppressing TLR-4/NF-κB pathway. [ Drug Des Devel Ther, 2019, 13:3391-3404] | PubMed: 31576113 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。